Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL4867261 | 1.00 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperidine SCHEMBL16927692 | 0.98 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Pyrrolidine SCHEMBL2531422 | 0.98 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Pyrrolidine SCHEMBL16241174 | 0.96 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Azetidine SCHEMBL28290955 | 0.94 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Aziridine SCHEMBL5185484 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperazine SCHEMBL7635861 | 0.90 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Piperazine SCHEMBL5875357 | 0.90 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Cyclohexane SCHEMBL27563472 | 0.88 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E | |
| Cyclopropane SCHEMBL2101355 | 0.88 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107652247-B | Preparation method of 2-methyl-3- [4, 5-dihydroisoxazole ] -4-methylsulfonyl ethyl benzoate | 黄河三角洲京博化工研究院有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-105541664-B | A kind of method for synthesizing cyanoacrylate | 潍坊同业化学有限公司 | 2018-01-30 | — | — | CN | claimed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | claimed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | claimed |
| EP-0131587-B1 | STATIC REDUCTION IN MAGNETIC RECORDING CASSETTES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-04 | — | — | EP | claimed |
| US-3988159-A | Light-sensitive material containing nitrone for forming heat-fixed images | AMERICAN CAN COMPANY (US) | 1976-10-26 | — | — | US | claimed |
| EP-4479050-A1 | USE OF NIRAPARIB FOR THE TREATMENT OF BRAIN CANCER | Tesaro, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-117222644-A | 2- ((4- ((S) -2- (4-chloro-2-fluorophenyl) -2-methylbenzo [ d ] [1,3] dioxol-4-yl) piperidin-1-yl) methyl) -1- (((S) -oxetan-2-yl) methyl) -1H-imidazole derivatives as GLP1 receptor activators for the treatment of obesity | 诺华股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023159066-A1 | USE OF NIRAPARIB FOR THE TREATMENT OF BRAIN CANCER | TESARO, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| EP-2420891-B1 | Process for immersion lithography | ROHM & HAAS ELECT MAT (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| US-4722017-A | NONVOLATILE, ELECTROCONDUCTIVE ORGANIC COATING | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-01-26 | — | — | US | disclosed |
| US-4570197-A | COATING OF ELECTOCONDUCTIVE ORGANIC COATING | MINNESOTA MINING & MANUFACTURING COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0131587-A1 | STATIC REDUCTION IN MAGNETIC RECORDING CASSETTES. | MINNESOTA MINING & MFG (US) | 1985-01-23 | — | — | EP | disclosed |
| WO-1984002798-A1 | STATIC REDUCTION IN MAGNETIC RECORDING CASSETTES | MINNESOTA MINING & MFG (US) | 1984-07-19 | — | — | WO | disclosed |
| US-4343891-A | CONVERTING TO COMPOUND HAVING FEWER THAN FOUR CARBON-TO-BORON BONDS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4313978-A | Antistatic compositions and treatment | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-3988159-A | Light-sensitive material containing nitrone for forming heat-fixed images | AMERICAN CAN COMPANY (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | ALDH1A1 378/4885SMN1; SMN2 4813/4885LMNA 4665/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | ALDH1A1 378/4885SMN1; SMN2 4813/4885LMNA 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.